KRAS Mutation and Metastatic Colorectal Cancer

KRAS mutation and metastatic colorectal cancer
Cetuximab is not as effective therapy for metastatic colorectal KRAS-mutatedTumors, however, point out anecdotal reports that, a minority of patients respond-some with long-term stabilization. De Roock and his colleagues examined the relationshipbetween KRAS mutation status and survival in a retrospective study of 579 patients withtreat chemotherapy-refractory metastatic colorectal cancer with cetuximab and foundthat patients with KRAS mutations p.G13D had longer overall survival and progression-free survivalthan patients with other mutations in KRAS.